Products are for professional/laboratory use only.
Streck has developed MDx-Chex™ for BCID2, a full-process quality control for sepsis tests.
The product contains 33 microorganisms and 10 resistance genes associated with sepsis and can be used for verification and monitoring of lot-to-lot performance of sepsis tests. MDx-Chex for BCID2 is For Research Use only. Not for use in diagnostic procedures. 
MDx-Chex for BCID2 contains all the intact microorganisms (inactivated) and resistance gene markers that the assay tests for. Comprised of a matrix of stabilized RBCs, WBCs and blood culture media components, it is packaged in a two-vial system ̶ a Gram (-) vial and a Gram (+) plus yeasts vial.
MDx-Chex for BCID2 is the most patient-like formulation available for sepsis tests and will verify the entire analytical process: cell lysis, DNA extraction and purification, qPCR and analysis. No other commercial option is as complete, with coverage and verification of all 43 targets using only two BCID2 pouches.
Features
- Comprised of inactivated microorganisms in a matrix of blood cells and culture media components to simulate a patient sample.
- Two sample-to-result tests needed for complete coverage of all 43 targets, which are contained in two vials.
- Allows for direct use on the sample-to-result test platform.
Benefits
Challenges and verifies the entire analytical process of MDx-based sepsis assays:
- Cell lysis
- DNA extraction/purification
- PCR inhibition
- Detection analysis
- Results reporting
Saves the use of expensive sample-to-result cartridges:
- Use 2 cartridges vs. 6 cartridges.
- Provides complete target coverage.
Easy to use:
- Pipette like a patient sample from a blood culture bottle.
- No pooling of individual microorganisms needed.
